BiotechTube

triamcinolone acetonide (Triesence®)

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis

Conditions

Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis

Trial Timeline

Feb 1, 2013 → Mar 1, 2015

NCT ID
NCT01789320

About triamcinolone acetonide (Triesence®)

triamcinolone acetonide (Triesence®) is a phase 1/2 stage product being developed by Clearside Biomedical for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01789320. Target conditions include Uveitis, Intermediate Uveitis, Posterior Uveitis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT01789320Phase 1/2Completed

Competing Products

20 competing products in Uveitis

See all competitors
ProductCompanyStageHype Score
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
69
Baricitinib + AdalimumabEli LillyPhase 3
77
Ixekizumab Prefilled SyringeEli LillyApproved
85
adalimumabAbbViePhase 3
77
Adalimumab + Prednisone + PlaceboAbbViePhase 3
77
Adalimumab + Prednisone + PlaceboAbbViePhase 3
77
AdalimumabAbbVieApproved
85
FTY720 + Oral CorticosteroidNovartisPhase 2
52
AIN457NovartisPhase 3
77
MyforticNovartisPre-clinical
23
AIN457 + AIN457 + Placebo AIN457NovartisPhase 3
77
LFG316 + Conventional TherapyNovartisPhase 2
52
RanibizumabNovartisPhase 2
52
AIN457 + PlaceboNovartisPhase 3
77
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77
AEB071NovartisPhase 2
52
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77
Myfortic + DecortinNovartisPhase 3
77
AIN457 + AIN 457 + AIN457NovartisPhase 2
52
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77

Other Products from Clearside Biomedical

4 mg CLS-TA Suprachoriodal InjectionPhase 3
69
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinPhase 3
69
4mg CLS-TA Suprachoriodal Injection + Sham ProcedurePhase 3
69
suprachoroidal CLS-TA + suprachoroidal sham + IVT afliberceptPhase 3
69
4 mg CLS-TA + Sham + IVT afliberceptPhase 2
44